Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News Akari Therapeutics Plc AKTX

Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing inhibitors of acute and chronic inflammation which includes the complement system, the bioamine system and the eicosanoid system for the treatment of rare and orphan diseases. Its main product candidate includes Coversin, Coversin long acting and Coversin dual action. The firm earns majority of its revenues from United Kingdom. It operates mainly in United States and United Kingdom.


Recent & Breaking News (NDAQ:AKTX)

Akari Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Recent Pipeline Progress

GlobeNewswire 12 hours ago

Akari Therapeutics to Participate in the Cantor Oncology & HemOnc Conference

GlobeNewswire 5 days ago

Akari Therapeutics Announces $12.75 Million Registered Direct Offering

GlobeNewswire September 12, 2022

Akari Therapeutics Narrows Pipeline Focus

GlobeNewswire August 1, 2022

Akari Therapeutics Announces Positive Results from Recent Pre-Clinical Studies of Investigational PASylated® Nomacopan That Support the Potential to Advance Research Toward IND/IMPD for Clinical Trials in Geographic Atrophy

GlobeNewswire July 28, 2022

Akari Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Pipeline Progress

GlobeNewswire July 20, 2022

Akari Therapeutics Announces First Patient to Complete Course of Treatment in the Phase III Part A Clinical Trial of Investigational Nomacopan in Pediatric Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA)

GlobeNewswire July 7, 2022

Akari Therapeutics Announces the Appointment of Accomplished Biotech Executive Melissa Bradford-Klug as Chief Operating Officer to Lead Business Development and Company Growth Strategies

GlobeNewswire June 13, 2022

Akari Therapeutics Presents Results from the CASCADE and CORONET Studies in COVID-19 at the American Thoracic Society (ATS) 2022 Annual Meeting

GlobeNewswire May 19, 2022

Akari Therapeutics Reports Full Year 2021 Financial Results and Highlights Clinical Progress

GlobeNewswire May 16, 2022

Akari Therapeutics to Present Results from Compassionate Use of Nomacopan for COVID-19 (CORONET) and Identification of Clinical Deterioration Risk in COVID-19 (CASCADE) at the American Thoracic Society (ATS) 2022 Annual Meeting

GlobeNewswire May 11, 2022

Akari Therapeutics Announces Publication of Phase II Data of Investigational Nomacopan for the Treatment of Bullous Pemphigoid (BP) in JAMA Dermatology

GlobeNewswire May 10, 2022

Akari Presents Results from Two Preclinical Development Programs of Long-Acting PAS-Nomacopan in Geographic Atrophy (GA) Dry Age-Related Macular Degeneration and Nomacopan in Experimental Immune-Mediated Conjunctival Disease (EIC)

GlobeNewswire May 9, 2022

Akari Therapeutics to Present on Two Ongoing Programs Covering Age-Related Macular Degeneration and Diseases of the Surface of the Eye at The Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting

GlobeNewswire March 21, 2022

Akari Therapeutics Announces New Data Supporting Use of Drug Candidate Votucalis Targeting Difficult to Treat Pain and Itch

GlobeNewswire March 9, 2022

Akari Therapeutics, Plc Announces $9.0 Million Registered Direct Offering

GlobeNewswire March 8, 2022

Akari Therapeutics Appoints Rachelle Jacques as President and Chief Executive Officer

GlobeNewswire March 2, 2022

Akari Therapeutics Announces New Data Showing A Significant Role for Complement Activation in the Clinical Outcomes of U.S. Army Trauma Patients in Iraq and the Therapeutic Potential of Nomacopan for Treatment of Trauma

GlobeNewswire February 28, 2022

Akari Therapeutics to Present at BIO CEO & Investor Conference

GlobeNewswire February 11, 2022

Akari Advances Lung Program with Inhaled Nomacopan Focused on Early Treatment of Severe Exacerbations in Lung Diseases

GlobeNewswire January 26, 2022